Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2015-01-19 AGM Information
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
PDF Version
AGM Information Classification · 98% confidence The document is explicitly titled as a "Press release" and announces that GENFIT "TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON FEBRUARY 24, 2015". It details the date, time, location, and procedures for participation and voting at this meeting, including the publication of the Notice of Meeting and the availability of related documentation. This content directly relates to the preparation and scheduling of a General Shareholders' Meeting, making 'AGM Information' (AGM-R) the most appropriate classification, as it covers materials shared around the AGM, even if it's the announcement of the meeting itself.
2015-01-19 English
Version PDF
AGM Information Classification · 98% confidence The document is titled "GENFIT ANNONCE LA TENUE D'UNE ASSEMBLEE GENERALE MIXTE LE 24 FEVRIER 2015" (GENFIT ANNOUNCES THE HOLDING OF A COMBINED GENERAL MEETING ON FEBRUARY 24, 2015). It explicitly discusses the date, agenda, resolutions, and voting procedures for a General Meeting. This directly relates to shareholder meetings and the materials associated with them. The most appropriate classification is AGM Information (AGM-R), as it announces the meeting itself, which is a core component of AGM materials.
2015-01-19 French
Version PDF
Regulatory Filings Classification · 95% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE GENFIT AVEC LA SOCIETE CM-CIC SECURITIES" (Semi-annual review of the liquidity contract between GENFIT and CM-CIC Securities) and is dated January 9, 2015. It details the status of shares and cash held in a liquidity account as of December 31, 2014, compared to the previous period (June 30, 2014). This type of announcement, which reports on specific financial arrangements or transactions (in this case, liquidity management), is not explicitly covered by the main reporting categories (10-K, IR, ER). It is a specific corporate action/financial update. Since it is a press release detailing a specific financial arrangement review, it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the more specific categories like DIV, CAP, or SHA, but it is a formal communication to the market. Given the context of reporting on a specific financial contract review, RNS is the most appropriate fallback, although it shares characteristics with an Earnings Release (ER) or Interim Report (IR) in terms of periodicity, it focuses narrowly on the liquidity contract, not overall performance.
2015-01-09 French
PDF Version
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "HALF-YEAR REPORT ON GENFIT'S LIQUIDITY CONTRACT WITH CM-CIC SECURITIES" and provides comparative data between June 30, 2014, and December 31, 2014. This structure strongly indicates a report covering a period shorter than a full year, specifically a half-year update. This aligns directly with the definition of an Interim / Quarterly Report (IR). Although it is a report on a specific contract, the context of a 'half-year report' makes IR the most appropriate classification over a general Regulatory Filing (RNS) or a specific financial release (ER). The length (4054 chars) suggests it is the content itself, not just an announcement of content.
2015-01-09 English
PDF Version
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Press release" dated January 6th, 2015, announcing the successful completion of a cardiac safety study (QT/QTc study) for their drug candidate GFT505. It summarizes key findings, includes quotes from the CMO, and provides company boilerplate information. This format—a brief, timely announcement of a specific development or result—aligns best with an Earnings Release (ER) if it were financial results, but since it is a clinical/scientific update presented as a press release, it is most closely categorized as a general announcement. Given the options, it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal regulatory filing like DVA or DIRS. It is a specific, non-financial operational update released via press release. The closest fit among the provided codes for a general, non-financial, non-earnings announcement is often the 'Regulatory Filings' (RNS) as a catch-all for press releases that don't fit other specific categories, or potentially an 'Audit Report / Information' (AR) if the study results were considered a form of regulatory validation/testing result, but AR is usually for internal/regulatory stress tests or formal audit reports. Since this is a press release announcing a clinical trial outcome, and it is not a formal financial report, a management discussion, or a specific corporate action (like M&A or dividend), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing clinical progress.
2015-01-06 English
Version PDF
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and dated January 6, 2015. It announces the successful completion of a clinical safety study (cardiac QT/QTc study) for the drug GFT505, detailing the methodology, results (no adverse effect on cardiac electrical activity), and commentary from the CMO. This format—a brief, timely announcement of a specific corporate or clinical event via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it announces a key operational/clinical milestone rather than just a report publication (RPA), the most fitting category for a press release announcing key operational/clinical results is the Earnings Release (ER) category, which often encompasses significant operational updates beyond just quarterly financials in the context of a biotech company. Given the content is a clinical trial update, it functions as a major operational announcement, similar to an earnings release highlighting performance/progress. If a more specific clinical trial update category existed, it would be preferred, but among the given options, ER is the closest fit for a major, time-sensitive announcement of results.
2015-01-06 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.